Bicara Therapeutics Inc. (BCAX) News
Track canonical SquawkNews coverage tagged to BCAX, Bicara Therapeutics Inc.. This hub brings together deduplicated headlines about alpaca us equities, markets catalysts, earnings, analyst actions, and wider market events so traders can review how a developing story changed over time. It contains 8 indexed stories across 6 publication days and is ordered by the same first-publication timeline used by LiveCast.
L
Bicara Therapeutics awards inducement grants under Nasdaq Rule 5635(c)(4)
Bicara Therapeutics said it awarded inducement grants on Sept. 1, 2026 to two new employees under Nasdaq Listing Rule 5635(c)(4).
EQUITY | Sep 03, 2026, 12:37 PM UTC
L
BCAX - Bicara Therapeutics Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
BCAX - Bicara Therapeutics Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
EQUITY | Sep 03, 2026, 12:30 PM UTC
M
BCAX reiterates Market Outperform, sets $31 price target
Hammerstone MarketTalk says BCAX reiterates Market Outperform and assigns a $31 price target after a Q2 update at Citizens.
EQUITY | Aug 21, 2026, 11:08 AM UTC
L
BCAX upgraded to Outperform with $35 price target at BMO
BCAX is rated Outperform and given a $35 price target by BMO, according to Hammerstone MarketTalk.
EQUITY | Aug 19, 2026, 11:48 AM UTC
L
BMO, Wedbush, Wolfe and RBC issue stock initiations
BMO, Wedbush, Wolfe, RBC and Cantor initiate coverage with ratings changes on AKTS, ALNY, ASND, BCAX, BMRN, CATX, PRME, AFL, AGMB, COR and MCK.
EQUITY | Aug 19, 2026, 11:09 AM UTC
L
Bicara Therapeutics announces Nasdaq Rule 5635(c)(4) inducement grant
Bicara Therapeutics (BCAX) announces an inducement grant under Nasdaq Listing Rule 5635(c)(4), as stated in the provided release text.
REGULATION | Aug 14, 2026, 12:30 PM UTC
L
BCAX - Bicara Therapeutics to Report Second Quarter 2026 Financial Results and Business Updates on August 11, 2026, at 8:30 AM ET - Click Fo
BCAX - Bicara Therapeutics to Report Second Quarter 2026 Financial Results and Business Updates on August 11, 2026, at 8:30 AM ET
EARNINGS | Aug 04, 2026, 12:30 PM UTC
L
Bicara Therapeutics Insider Sold Shares Worth $833,129, According to a Recent SEC Filing
() -- Ryan Cohlhepp, Director, President and COO, on July 08, 2026, sold 28,750 shares in Bicara Therapeutics (BCAX) for $833,129. Following the Form 4 filing with the SEC, Cohlhepp has control over a total of 181,641 co
GEOPOLITICS | Jul 10, 2026, 08:20 PM UTC